Milestones & Recognitions

We acquired Pola Pharma in Japan to strengthen our global dermatology presence

We launched our specialty product, Cequa in the United States for the treatment of dry eyes

We entered Greater China market through partnership with China Medical System Holdings

We launched specialty product, ILUMYA™ (tildrakizumab-asmn) in the United States for treatment of moderate-to-severe plaque psoriasis

We launched specialty product, Odomzo in USA

We acquired 14 brands from Novartis in Japan

We acquired Ocular Technologies, Sarl to strengthen our branded ophthalmic portfolio

We acquired Biosintez to enhance our presence in Russian market

We launched our first branded ophthalmic product, BromSite™ in USA

We acquired GSK’s Opiates business in Australia

We acquired InSite Vision Inc. to strengthen our branded ophthalmic portfolio in USA

We acquired Ranbaxy in a US$ 4 billion landmark transaction to create the world’s 5th largest specialty generic pharmaceutical company

Sun Pharma and Merck & Co. Inc. entered into licensing agreement for Tildrakizumab (MK- 3222)

We acquired Pharmalucence in USA

We acquired Dusa Pharmaceuticals and the generic business of URL Pharmaceuticals in USA

We acquired controlling stake in Israel-based Taro Pharmaceuticals, headquartered in USA to effectively double company’s US business

We acquired Chattem Chemicals Inc, USA

We demerged Sun Pharma Advanced Research Company (SPARC) into a separate entity

We completed buyout of manufacturing unit in Bryan, Ohio, USA

We acquired ICN’s business in Hungary from Valeant Pharma

We set up a new formulation unit in Jammu, India

We commissioned the first joint venture manufacturing unit in Dhaka, Bangladesh

We acquired Phlox Pharma (India) and niche brands from Women’s First Healthcare (USA)

We commenced production at our new formulations unit in Dadra, India

We acquired Pradeep Drug Company in India

We acquired Milmet Labs, Cephalexin and 7ADCA actives manufacturing site in India

We began operations at a new formulation unit in Silvassa, Gujarat, India

We purchased equity stakes in TDPL and MJ Pharma

We had our first international acquisition – Caraco Pharmaceutical Laboratories, USA (completed 100% acquisition in 2010)

We established new research facility in Mumbai, India

We expanded our sales network across 24 countries

We acquired API plant from Knoll Pharma at Ahmednagar, Maharashtra, India

We began production at API manufacturing plant in Panoli, Gujarat, India

We launched Initial Public Offering (IPO)

We established our first research center to create a base for strong product and process development

We launched Monotrate and Angize, our first cardiology products

Sun Pharma established with five psychiatry products and a two-person marketing team

Sun Pharma set up our first manufacturing facility for tablets and capsules at Vapi, Gujarat, India

We were recognised as the #1 generic pharmaceutical company by patient groups in the annual PatientView ‘Corporate Reputation of Pharma’ survey 2021

We received the Golden Peacock Award for Corporate Social Responsibility, 2020

We won the Dun & Bradstreet India Corporate Award under the Sectoral Performance-based category- Pharmaceuticals

We bagged the DIANA (Distribution Industry Award for Notable Achievements in Healthcare) award for ‘Best New Product Introduction/Promotion’ at the Annual Healthcare Distribution Alliance Conference 2021

We were recognized as the Best Innovative Company of the Year 2021 at Indo-American Corporate Excellence Awards.

We were listed among the Forbes World’s Best Employers 2020

Volini, one of our star OTC products was named in Nielsen BASES Top Breakthrough Innovation Winners India 2020 list

We ranked No. 1 in pharma sector and No. 16 overall in the BW Businessworld list of India’s Most Respected Companies

We were listed among the Forbes World’s Best Regarded companies

Our CSR subsidiary, Foundation for Disease Elimination and Control of India was conferred with Mahatma Award for Social Good 2019

Our Mobile Healthcare Unit project was recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum

We were listed among the Forbes World’s Most Innovative companies

We were listed among the Forbes World’s Best Employers

We received Outstanding Contribution in CSR recognition from the Federation of Gujarat Industries

We received Best CSR Practices Award from The Economic Times

Dilip Shanghvi received Lifetime Outstanding Achievement Award from the Indore Management Association

Dilip Shanghvi received Entrepreneur of the Year Award from the All India Management Association (AIMA)

We received DIANA (Distribution Industry Award for Notable Achievements) Award from Healthcare Distribution Alliance, USA

We received Community Care Award from ASSOCHAM (Associated Chambers of Commerce)

Dilip Shanghvi was honoured with Padma Shri (fourth highest civilian award in India) by the Government of India

We received India Pharma Research Development Award 2015 from the Ministry of Chemicals & Fertilizers, Government of India

We received Excellence in CSR Award from UBM-India

Dilip Shanghvi was recognised by NDTV as ‘Business Leader of the Year’

We were listed among the Forbes World 100 Most Innovative Companies

We received Cardiovascular Pharmaceutical Company of the Year Award at the Frost & Sullivan India Healthcare Excellence Awards

Dilip Shanghvi received JRD TATA Corporate Leadership Award from All India Management Association (AIMA)

Dilip Shanghvi received Entrepreneur of the Year Award from Forbes

Dilip Shanghvi received Business Leader of the Year Award from The Economic Times

Sun Pharma was named Company of the Year by The Economic Times

Sun Pharma was named Company of the Year by Business Standard

We were listed among Forbes Asia’s Fab 50 Companies

Uday Baldota received Best CFO in Pharma and Healthcare Award at the CNBC TV-18 CFO Awards

We won NDTV Profit’s Business Leadership of the Year Pharmaceutical Award

Sun Pharma was named Most Outstanding Company of the Year at the CNBC-TV18 India Business Leader Awards

We were listed in Forbes Asia’s Fab 50 Companies

We were listed among Forbes World’s 100 Most Innovative Companies

We were hailed as the Pharmaceutical Company of the Year at the Frost & Sullivan India Healthcare Excellence Awards

Sudhir V. Valia was named Best CFO in Pharma and Healthcare at the CNBC-TV18 CFO Awards

Dilip Shanghvi was recognised as World Entrepreneur of the Year by Ernst & Young

Dilip Shanghvi was recognised as Indian of the Year (Business) by CNN IBN

Dilip Shanghvi was honoured with Businessman of the Year Award by Business India

We received Business Leadership of the Year Award by NDTV PROFIT

Dilip Shanghvi received Entrepreneur of the Year Award by Ernst & Young

We received Rolta Corporate Award – Pharmaceuticals by Dun & Bradstreet

Sudhir V. Valia was named Best CFO in Pharma and Healthcare at the CNBC-TV18 CFO Awards

We won Outstanding Exporter of the Year- Pharmaceuticals, Healthcare and Life Sciences Award at the CNBC TV 18 The International Trade Awards

We received NDTV Profit’s Business Leadership Award

Dilip Shanghvi was named CEO of the Year by Business Standard

Dilip Shanghvi was honoured with Entrepreneur of the Year Award by The Economic Times

Dilip Shanghvi won Pharmaceutical Companies IMC Juran Quality Medal IMC Ramkrishna Bajaj at the National Quality Award Trust

Dilip Shanghvi was recognised as First Generation Entrepreneur of the Year by CNBC-TV18

Dilip Shanghvi was named Entrepreneur of the Year (Healthcare and Life Science) by Ernst & Young